Eli Lilly and Company

Jiehao Chen

Daniel Jon Sall

Jolie Anne Bastian

James Robert Henry

William Thomas McMillen

Jeffrey Daniel Cohen

Gaiying Zhao

Almudena Rubio

Bradley Earl Reaman

William Thomas Mcmillen

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. 

1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer

The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

2,3-dihydro-1H-indole compounds

Growing community of inventors

Carmel, IN, United States of America

Jiehao Chen